Saturday, February 14

Is Weakness In Exasol AG (ETR:EXL) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?


Exasol (ETR:EXL) has had a rough three months with its share price down 17%. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Specifically, we decided to study Exasol’s ROE in this article.

ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In simpler terms, it measures the profitability of a company in relation to shareholder’s equity.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders’ Equity

So, based on the above formula, the ROE for Exasol is:

31% = €1.9m ÷ €6.0m (Based on the trailing twelve months to June 2025).

The ‘return’ refers to a company’s earnings over the last year. So, this means that for every €1 of its shareholder’s investments, the company generates a profit of €0.31.

See our latest analysis for Exasol

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Depending on how much of these profits the company reinvests or “retains”, and how effectively it does so, we are then able to assess a company’s earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don’t have the same features.

First thing first, we like that Exasol has an impressive ROE. Second, a comparison with the average ROE reported by the industry of 23% also doesn’t go unnoticed by us. As a result, Exasol’s exceptional 46% net income growth seen over the past five years, doesn’t come as a surprise.

Next, on comparing with the industry net income growth, we found that Exasol’s growth is quite high when compared to the industry average growth of 11% in the same period, which is great to see.

past-earnings-growth
XTRA:EXL Past Earnings Growth November 27th 2025

Earnings growth is an important metric to consider when valuing a stock. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Exasol is trading on a high P/E or a low P/E, relative to its industry.

Given that Exasol doesn’t pay any regular dividends to its shareholders, we infer that the company has been reinvesting all of its profits to grow its business.

In total, we are pretty happy with Exasol’s performance. In particular, it’s great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. Having said that, the company’s earnings growth is expected to slow down, as forecasted in the current analyst estimates. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *